Eisai Wins Approval Of Sedative Lusedra, But Without Main Marketing Advantage
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA approved Eisai's intravenous sedative-hypnotic agent Lusedra (fospropofol), but without the marketing advantage the company was hoping it would used to help differentiate the anesthetic from its competitors
You may also be interested in...
Eisai Sees Generics Opportunity In Japan For Innovator Companies
A push by the Japanese government to increase generic drug utilization is an opportunity for innovator companies to jump into the generics space following Japanese patent expiries, according to Eisai CEO Haruo Naito
Eisai Sees Generics Opportunity In Japan For Innovator Companies
A push by the Japanese government to increase generic drug utilization is an opportunity for innovator companies to jump into the generics space following Japanese patent expiries, according to Eisai CEO Haruo Naito
U.S. FDA Rejects Eisai’s Aquavan Injection
Despite a recent advisory panel vote recommending clearance, albeit with strings attached, U.S. FDA has deemed Eisai's Aquavan, a mild-to-moderate sedative for colonoscopies and other procedures, "not approvable.